Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 55.00 9,603 08:00:00
Bid Price Offer Price High Price Low Price Open Price
53.00 57.00 55.00 55.00 55.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.74 -2.24 -2.49 48
Last Trade Time Trade Type Trade Size Trade Price Currency
12:56:35 O 1,000 53.00 GBX

Optibiotix Health (OPTI) Latest News

More Optibiotix Health News
Optibiotix Health Takeover Rumours

Optibiotix Health (OPTI) Discussions and Chat

Optibiotix Health Forums and Chat

Date Time Title Posts
06/8/202021:18OptiBiotix Health PLC - 9,030
06/8/202013:11OptiBiotix - The uncensored thread 23,216
01/8/202020:46OptiBiotix Health (Facts NOT Fiction)5,109
10/6/202012:27OptiBiotix Health PLC - Products & Partner Listings7
08/6/202021:08SentimentalRules AKA idoflykathy74

Add a New Thread

Optibiotix Health (OPTI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-06 11:56:3653.001,000530.00O
2020-08-06 11:55:5953.001,000530.00O
2020-08-06 11:34:2153.251,350718.88O
2020-08-06 10:35:3853.005,0002,650.00O
2020-08-06 09:36:3453.001,000530.00O
View all Optibiotix Health trades in real-time

Optibiotix Health (OPTI) Top Chat Posts

DateSubject
06/8/2020
09:20
Optibiotix Health Daily Update: Optibiotix Health Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 55p.
Optibiotix Health Plc has a 4 week average price of 47p and a 12 week average price of 47p.
The 1 year high share price is 72p while the 1 year low share price is currently 24p.
There are currently 87,940,601 shares in issue and the average daily traded volume is 152,515 shares. The market capitalisation of Optibiotix Health Plc is £48,367,330.55.
24/7/2020
08:17
robo28: Well as an investor, I measure a company on a few things , are revenues building ? Yes, is the company's product/ service in Demand ?YES . Who's running the company , do they have a track record? Yes, can the company's product be sold in different country's and territories?? Yes , so Opti for me ticks all those boxes and historically when a company transitions into profit the share price goes up , this next year or so I see Opti at 3 times these levels at least
23/7/2020
16:36
manc10: agree the share price is garbage but the company is building up very well hopefully the share price will follow i am as frustrated as the next man but the company is growing year on year build the company and the share price will follow compared to when i first invested opti did not have one product thats a fact a rallying call will be money to the bottom line thats it
10/7/2020
08:15
buywell3: Lest we forget In my view, this interview with Opti's CEO throws up a number of red flags whilst the company is valued at £55m but yet to produce any revenues:- hTTp://www.tiptv.co.uk/archives/interview-with-the-optibiotix-health-plc-ceo/ 1) Note how often the CEO refers to the share price. CEO should be talking about revenues and profits not the share price. Needless to say, not once are revenues and potential profits mentioned. 2) He appears to think that because peer group companies are highly over-valued then OptiBiotix shares should be highly over-valued too. Ridiculous. It just means the whole sector may be due a nasty surprise. 3) The CEO mentions the whole market opportunity but never once tells investors what slice OptiBiotix are likely to achieve. 4) He keeps referring to growth, but what does he mean since no dates are given regarding revenues let alone profits. What company growth has been achieved then? Headcount and outgoings? 5) CEO says the following :- "The sugars will come much later that's really cutting edge science and that's where the biggest opportunity is". In other words, their biggest market is still light years away. Investors should expect plenty of dilutive placings in the next few years. 6) The first market that they are going to address is the over the counter supplements market. This is a market that is already massively over-crowded. Marketing spend would be huge just to make the slightest penetration. 7) He recognises that Asian markets are a problem. They will just pinch the IP without so much as a by-your-leave. I notice that investors were getting over-excited about a sugar tax today. LOL. See point (5). Revenues and profits are years away yet, and the company is valued at £55m. Who knows what will happen to the share price in the short term, but if I'd made a decent profit already I'd take it off the table because the slightest smell of missed deadlines, disappointments and/or delays with soon smash the share price. There is no margin of safety. Investors will need a constant flow of jam tomorrow RNS's and continued ramping to keep the share price moving forward. Otherwise...............
06/6/2020
18:34
spartan attack: Interview with Optibiotix CEO in August 2017 share price circa 65p - TODAY 55.6p ....................................... Can you tell me what all this means for OptiBiotix Health investors? "I think it looks very promising for investors and of course, I am probably the largest single private investor and my family have a large stake holding in the company, many of those bought at 75p and we’re below that now. So, as I said at the start of this interview, I want to reassure investors that the fluctuation in share price don’t worry me " Well in fairness, investors had no averaging down options such as recent placing or, CLN deal offering yield and 50% discount on IPO initial price for probiotix. So i can understand why he is not worried really........... "Investors should also note, if they look up Biopharma or Pharmabiota, these companies have a very good reputation for investing in scientifically validated products which they sell into the high-value pharmaceutical market." Ok but three years later nearly, Its record earnings losses? "I just hope investors can start to see the momentum building up as we create multiple partnerships across multiple territories with each partner starting to contribute small amounts but incrementally increasing to grow revenue. We see this as a very low risk, low cost approach to accessing multiple healthcare markets and pharmaceuticals markets across the world which, if we’re successful in this, we can generate 7-figure revenues in the forthcoming years." Well the margins and sales volumes seem debatable at the very least. Low cost approach? Anyone send em a memo? 7 figure revenues in forthcoming years? Wow. This Market Cap to only aim for 7 figure numbers in "years". But he said revenues. Earnings are very different. An earnings forecast would be appreciated
27/5/2020
14:08
spartan attack: i never even mentioned sbtx. Well done But back to opti..,, manc1027 May '20 - 14:02 - 19685 of 19685 0 0 0 as soh says he is building a company not a share price the share price will follow the fundamentals not what the 3 stoogies say or i say ................ ok. But if thats the case, why are the fundamentals that share price will follow - only half the value v 2018? With all that extra news on deals and 900%+ on sales etc?
27/5/2020
14:05
spartan attack: manc1027 May '20 - 14:02 - 19685 of 19685 0 0 0 as soh says he is building a company not a share price the share price will follow the fundamentals not what the 3 stoogies say or i say ................ ok. But if thats the case, why are the fundamentals that share price will follow - only half the value v 2018? With all that extra news on deals and 900%+ on sales etc?
22/5/2020
20:34
spartan attack: htTps://www.globenewswire.com/news-release/2020/04/27/2022701/0/en/Update-on-Omega-Optibiotix-and-NAVs.html April 27, 2020 13:52 ET | Source: Seneca Growth Capital VCT PLC Seneca Growth Capital VCT Plc (the "Company") Partial Realisations of Ordinary Share Investment in Omega Diagnostics Group plc (“Omega”) and B Share Investment in Optibiotix Health plc (“Optibiotix”), and updated Ordinary Share and B Share Net Asset Values (“NAV”) Partial Realisations of Ordinary Share Investment in Omega and B Share Investment in Optibiotix Following the recent rise in Omega’s share price on AIM, the Company has sold a further 543,868 Omega shares realising £211,940. The Company has now sold a total of 1,693,868 Omega shares from the Ordinary Share pool since the year end, realising a total of £570,636 and generating a profit versus original cost of £328,430 (equivalent to an unaudited profit of 136%). The Company’s Ordinary Share pool retains 600,000 Omega shares. The Directors are also pleased to report that the Company has sold 150,000 Optibiotix shares from the B Share pool, realising £90,083 and generating a profit versus original cost of £30,083 (equivalent to an unaudited profit of 50%). The Company’s B Share pool retains 600,000 Optibiotix shares
09/5/2020
14:57
kreature: Very encouraging. Thanks Colin/manc..... —- manc109 May '20 - 13:08 - 3697 of 3701 0 0 0 OPTI from colin z on the no nutjob thread Deals 40-50 ongoing discussions at the moment, some of which have been going on for a while, “a number of years”. Won’t give more on H&B sales but has ‘surpassedR17; SoH’s expectations, he’s ‘pleased’; with all of the retail deals so far. Retailers give volume, not margin. Total number of deals is 62 (64 including the ones this week), majority of these are ‘still active’. 4-5 ‘not active’ e.g. Medicum?? distributor deal dead – OPTI have gone direct with Velinoff Pharma. Still looking at India retail. 40/62 deals now producing revenues. Fred helped to grow revenues for his division. 70% of deals are generating revenues within the first year of signing in 2020 vs. 30% in 2018. SoH doesn’t think SBTX shareholders appreciated the Croda deal. Cash / Revenue “We don’t expect to raise more money, focus this year is on reaching profitability” – doesn’t rule it out in future though to grow the company. Recently raised funds enough to sustain working capital needs for recent US and China deals. Q1 2020 prebiotic division (Fred Narbel) has reached profitability. Trading statement over next week. 2019 accounts waiting to come back from the auditors. Seed still selling c$1m a month in product. Revenue growth: 2500% prebiotics, 69% online (80-85% gross margin), 14% probiotics (n.b no context given re period). Future Looking to incorporate Slimbiome into bread and crisps: “Protein and slimbiome crisps”. Market trend towards healthy snacking, OPTI developing products to meet this. Granja Pocha to ‘prove’ they can take LPLDL into dairy. GMP still very ‘high risk’ (I believe this is US pharma LPLDL deal). Billion-dollar opportunity is unrealistic (SoH referring to bulletin board comments on what the company could be worth). When asked about 2022 pre-tax profits of £7-10m he came back with “We’re at the early stage of generating revenues” focus on this year getting to profitability. “Not going to predict two, three years down the line”. Prebiotic should be “very profitable” by the end of the year, probiotic division “not there yet”…220;quite a gap to fill”. Probiotics possible spinout on AIM/NASDAQ…Q. Why? A. Meetings facilitated by Goetz in Europe – potential investors concerned about the AIM listing and how the share price is not reflective of company progress – more influenced by bloggers than company news (TW called this out as a weak argument). SoH came back with NASDAQ companies’ valuations being 10-20x OPTI value, when compared – Americans realise the potential of the microbiome vs. Europeans. OPTI trying to expand US product listings (Seed, Costco, Walmart) to increase visibility of the company and its products that will help to support a future NASDAQ listing.
09/5/2020
13:08
manc10: OPTI from colin z on the no nutjob thread Deals 40-50 ongoing discussions at the moment, some of which have been going on for a while, “a number of years”. Won’t give more on H&B sales but has ‘surpassedR17; SoH’s expectations, he’s ‘pleased’; with all of the retail deals so far. Retailers give volume, not margin. Total number of deals is 62 (64 including the ones this week), majority of these are ‘still active’. 4-5 ‘not active’ e.g. Medicum?? distributor deal dead – OPTI have gone direct with Velinoff Pharma. Still looking at India retail. 40/62 deals now producing revenues. Fred helped to grow revenues for his division. 70% of deals are generating revenues within the first year of signing in 2020 vs. 30% in 2018. SoH doesn’t think SBTX shareholders appreciated the Croda deal. Cash / Revenue “We don’t expect to raise more money, focus this year is on reaching profitability” – doesn’t rule it out in future though to grow the company. Recently raised funds enough to sustain working capital needs for recent US and China deals. Q1 2020 prebiotic division (Fred Narbel) has reached profitability. Trading statement over next week. 2019 accounts waiting to come back from the auditors. Seed still selling c$1m a month in product. Revenue growth: 2500% prebiotics, 69% online (80-85% gross margin), 14% probiotics (n.b no context given re period). Future Looking to incorporate Slimbiome into bread and crisps: “Protein and slimbiome crisps”. Market trend towards healthy snacking, OPTI developing products to meet this. Granja Pocha to ‘prove’ they can take LPLDL into dairy. GMP still very ‘high risk’ (I believe this is US pharma LPLDL deal). Billion-dollar opportunity is unrealistic (SoH referring to bulletin board comments on what the company could be worth). When asked about 2022 pre-tax profits of £7-10m he came back with “We’re at the early stage of generating revenues” focus on this year getting to profitability. “Not going to predict two, three years down the line”. Prebiotic should be “very profitable” by the end of the year, probiotic division “not there yet”…220;quite a gap to fill”. Probiotics possible spinout on AIM/NASDAQ…Q. Why? A. Meetings facilitated by Goetz in Europe – potential investors concerned about the AIM listing and how the share price is not reflective of company progress – more influenced by bloggers than company news (TW called this out as a weak argument). SoH came back with NASDAQ companies’ valuations being 10-20x OPTI value, when compared – Americans realise the potential of the microbiome vs. Europeans. OPTI trying to expand US product listings (Seed, Costco, Walmart) to increase visibility of the company and its products that will help to support a future NASDAQ listing.
23/4/2020
11:39
sentimentrules: Whatever comforts you nobby..in your time of opti share price destruction
Optibiotix Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
OPTI
Optibiotix..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200807 05:15:07